Background
Methods
Search strategy and identification of studies
Selection criteria
Data extraction and quality assessment
Data synthesis and analysis
Results
Study selection and characteristics
Author and reference | Year Published | Journal | Study Country | Study population | Study design | Patient Age Range |
---|---|---|---|---|---|---|
Boisen et al. [19] | 2018 | Scientific Reports | Sierra Leone | Suspected Lassa fever patients and their contacts | Prospective cohort | not stated |
Boisen et al. [19] | 2018 | Scientific Reports | Sierra Leone | Suspected Lassa fever patients and their contacts | Prospective cohort | not stated |
Bausch et al. [20] | 2000 | Journal of Clinical Virology | Sierra Leone and Guinea | Suspected Lassa fever patients | Prospective cohort | not stated |
Gabriel et al. [21] | 2017 | PLOS Neglected Tropical Diseases | Nigeria, Ghana and Germany | Suspected Lassa fever patients | Prospective cohort | not stated |
Ibekwe et al. [22] | 2012 | Nigerian Medical Journal | Nigeria | Clinically diagnosed patients and referred suspected patients | Case-control | 11–61 years |
Meulen et al. [23] | 1998 | Journal of Clinical Microbiology | Guinea and Liberia and Germany (Hamburg) | Patients with fever of unknown origin and hemorrhage | Cross-sectional | not stated |
Emmerich et al. [24] | 2006 | Journal of Clinical Virology | Nigeria, Liberia, Sierra Leone and Guinea | Healthy adult blood donors | Cross-sectional | 18–53 |
Olschlager et al. [25] | 2010 | Journal of Clinical Microbiology | Liberia and Nigeria | Laboratory confirmed Lassa patients | Cross-sectional | not stated |
Trappier et al. [26] | 1993 | American Journal of Tropical Medicine and Hygiene | Sierra Leone | Suspected Lassa fever patients | Cross-sectional | not stated |
Author | Test Name | Reference Test | Type of Samples | Number of Samples Tested | Type of evaluation | Sensitivity(95% CI) | Specificity(95% CI) |
---|---|---|---|---|---|---|---|
Boisen et al | Recombinant Lassa Virus Rapid Diagnostic Test (ReLASV RDT) | Nikisins qPCR | Serum and plasma | 451 | Field evaluation | 91.2(75.2–97.7) | 86(71.4–94.2) |
ReLASV Ag ELISA | Serum and plasma | 451 | Field evaluation | 94.8(81.3–99.1) | 100(88.6–100) | ||
Boisen et al | Recombinant Lassa Virus Antigen ELISA(ReLASV Ag ELISA) | Nikisins qPCR | Serum and plasma | 451 | Field evaluation | 91.2(75.2–97.7) | 86(71.4–94.2) |
Bausch et al | Combined ELISA Antigen/IgM assay | Virus Isolation | Serum | 305 | Laboratory | 88(77–95) | 90(88–91) |
Indirect Immunofluorescent antibody test | Virus Isolation | Serum | 305 | Laboratory validation | 70(57–81) | 88(85–90) | |
Gabriel et al | IgM ELISA | Standard RT-PCR | Serum | 270 | Laboratory | 31.1(25.6–37) | 95.7(92.8–97.7) |
Recombinant IgM/IgG ELISA | Standard RT-PCR | Serum | 270 | Laboratory | 25.9(20.8–31.6) | 100(98.2–100) | |
Ibekwe et al | IgM ELISA | Standard RT-PCR | Serum | 72 | Laboratory | 57(41.05–72.95) | 77(63.06–90.94) |
Meulen et al. | IgM/IgG Immunoblot | Indirect Immunofluorescent assay(IFA) | Serum | 157 | Laboratory | 90.7(84.13–97.27) | 96.3(92.2–100) |
Emmerich et al | Reverse IgG ELISA | IFA | Serum | 643 | Laboratory | 100(99–100) | 99(98–100) |
Olschlager et al | GPC RT-PCR(Qiagen) | Virus isolation | Serum and CSF | 77 + (1CSF sample) | Laboratory | 100(99–100) | |
Trappier et al | Conventional PCR | Virus Isolation | Serum | 195 | Laboratory | 66(55–77) | 78(69.5–84.5) |
Author Last | Test Name | Phase of infection | Funding source |
---|---|---|---|
Boisen et al | Recombinant Lassa Virus Rapid Diagnostic Test (ReLASV RDT) | Acute phase | NIH (National Institute for Health). Possible conflict of interest with Viral Hemorrrhagic fever Consortium. |
Boisen et al | Recombinant Lassa Virus Antigen ELISA (ReLASV Ag ELISA) | NIH (National Institute for Health). Possible conflict of interest with Viral Hemorrrhagic fever Consortium. | |
Bausch et al | Combined ELISA Antigen/IgM assay | Acute phase. Convalescent samples collected but data on testing not given. | American Association of Schools of Public Health (AASPH) & Tulane University |
Indirect Immunofluorescent antibody test | |||
Gabriel et al | IgM ELISA | Not clear | European Fund for regional development |
IgM/IgG ELISA | |||
Ibekwe et al | IgM ELISA | Acute phase | No funding source |
Meulen et al. | IgM/IgG Immunoblot | Not clear | Not stated |
Emmerich et al | Reverse IgG ELISA | Convalescent samples (from survivors) | Bundesamt f¨ur Wehrtechnik und Beschaffung |
Olschlager et al | GPC RT-PCR(Qiagen) | Not clear | Bundesamt f¨ur Wehrtechnik und Beschaffung |
Trappier et al | Conventional PCR | Not clear | Not stated |
Study | Assay | Reason |
---|---|---|
1- Fukuma et al, 2011 [27] | Reverse Transcription LAMP | No data on sensitivity and specificity. Just talks about assay development |
1- Fukushi et al, 2012 [28] | Serological assays | Review. No data on performance |
3- Pang et al, 2014 [29] | Multiplex one step Real-Time Taqman qRT-PCR | No data on sensitivity and specificity given. Not a lab or field evaluation. |
4- Das et al, 2015 [30] | Multiplex PCR/LDR assay | Not an evaluation. No data on sensitivity and specificity |
5- Jones A et al, 2011 [31] | Handheld multiplex POC diagnostics | No data on sensitivity and specificity |
6- Trombley et al, 2010 [32] | RT-TaqMan PCR | Not an evaluation study. No data on sensitivity and specificity |
7- Drosten et al, 2002 [33] | SYBR-green real time RT-PCR | Not a lab or field evaluation. |
8- Bukbuk et al, 2014 [34] | Recombinant NP(rNP) IgG ELISA | No data on sensitivity and specificity |
9- Barber et al, 1990 [35] | Recombinant ELISA | Not evaluated in humans. No data on sensitivity and specificity |
10- Li et al, 2009 [36] | Fluorescent microbeads based multiplex assay | No data on performance |
11- Saijo et al, 2007 [37] | Ag-Capture ELISA | No data on the performance |
12- Salvato et al, 2018 [38] | Review | |
13- Satterly et al, 2016 [39] | Ag and IgM Capture(MAGPIX) | |
14- Olschlager et al, 2012 [40] | RT-PCR/hybridization assay | No data on sensitivity and specificity |
15- Vieth et al, 2007 [41] | RT-PCR | Not an evaluation study |
16- Leski et al, 2009 [42] | High Density Resequencing microarray | No data on sensitivity and specificity. |
17- O’Hearn et al, 2016 [43] | IgG(MAGPIX) | No data on sensitivity and specificity |
18- Demby et al, 1994 [44] | Standard RT-PCR | Not an evaluation study |
19- Sebba D et al, 2018 [45] | Multiplex POC test for Lassa, Ebola and Malaria | None of the 276 clinical samples tested with the 3-plex assay were independently tested for LASV. |
20- Koehler et al, 2018 [46] | Highly Multiplex Broad Pathogen detection assay | No data on sensitivity and specificity. |